Respiratory Syncytial Virus Consortium in Europe
RESCUE is funded by the Innovative Medicines Initiative Joint Undertaking, cofunded by the European Commission FP7 Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA), and aims to gather information on the scale of RSV infection in Europe and its economic impacts, using this information to design best practice guidelines for monitoring of RSV and to shape future vaccination programmes.
The consortium will also identify biological markers associated with severe RSV infection to aid in diagnosis and facilitate the development of new treatments and vaccines. As partner, Penta will contribute to consolidation of health care systems data and lead activities around networking and linkage to Regulatory Authorities.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement Nº 116019. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. The amount of funding received in 2018 is 64.824 €.